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A 34-year-old black sales manager was referred for evaluation of
azotemia of undetermined duration. He claimed to be in good health
except for "borderline" hypertension since age 25. He had no history of
urinary tract signs or symptoms. A tumor of unspecified type had been
removed from the left anterior chest wall 8 years previously; there had
been no recurrence. A younger sister was a hemodialysis patient in
another city; the cause of her renal failure was unknown to the patient.
The family history included no deafness, hematuria, proteinuria, or
renal cysts.
The supine blood pressure was 160/100 mm Hg in both arms. The
fundi were normal. His hearing acuity was judged to be intact. The left
pectoralis major muscle had been removed surgically. Cardiovascular
examination was normal. The abdomen was soft and nontender, and no
masses were detected by palpation. Genital and rectal examinations
were normal.
The urine was negative for protein by dipstick examination. The urine
sediment revealed 5 to 10 erythrocytes/high-power field and contained
no casts or lipid bodies. The hemoglobin level was 13.4 g/dl and the
hematocrit was 37.6%. The white blood cell and platelet counts were
normal. Serum electrolyte levels were within normal limits. The serum
creatinine concentration was 3.4 mg/dl; serum urea nitrogen, 45 mg/dl;
serum calcium, 9,0 mg/dl; phosphate, 3.3 mg/dl; serum urate, 11.6
mg/dl; and alkaline phosphatase, 95 lU/liter. Total urinary protein
excretion was 48 mg/24 hours. The creatinine clearance was 35 mI/mm.
A renal scan with mTcDPTA showed prompt and symmetric flow
to both kidneys; the excretion of '311-Hippuran was symmetric and
slightly delayed; a furosemide washout test disclosed no evidence of
obstruction. Ultrasound examination revealed kidneys of normal size
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(each Il cm long) and position; renal parenchymal echogenicity was
increased in contrast to the liver. Multiple discrete cysts ranging from a
few mm to 2 cm in diameter were scattered throughout both kidneys.
Also present was a hyperechoic mass in the lower pole of the left kidney
that measured 3.5 cm in greatest dimension. A CT scan confirmed cysts
in both kidneys and none in the liver (Fig. 1) as well as a homogeneous
mass measuring 3.5 cm in diameter in the posterior aspect of the lower
pole of the left kidney. There was no evidence of retroperitoneal
adenopathy. A magnetic resonance scan confirmed the presence of
multiple bilateral renal cysts and suggested a mass in the left kidney
(Fig. 2). When the image was enhanced with gadolinium, the scan
suggested a neoplasm rather than a hemorrhagic cyst.
An operation was performed with the intention of removing the tumor
mass by subtotal nephrectomy. Frozen-section biopsy of several sus-
picious nodules in the left kidney revealed multifocal carcinoma,
however, and a total nephrectomy was performed. The large renal mass
was a papillary adenocarcinoma (Fig. 3), which had invaded but not
penetrated the renal capsule. No extrarenal involvement with tumor
was detected. The non-tumorous parenchyma showed global glomeru-
lar sclerosis, severe tubular atrophy, interstitial monolayer infiltrate and
fibrosis, and vascular sclerosis consistent with an end-stage process of
indeterminate cause. The serum creatinine level 2 weeks post operation
was 5.2 mg/dl.
Discussion
Dg. JARED J. GRANTHAM (Professor of Medicine; Director of
Division of Nephrology and Hypertension, University of Kan-
sas School of Medicine, Kansas City, Kansas): Acquired cystic
kidney disease (ACKD) is characterized by the development of
numerous fluid-filled cysts in the kidneys of individuals with
chronic progressive renal disorders who have no history of
hereditary cystic disease. In 1847, Simon initially described
ACKD in the kidneys of patients with subacute glomerulone-
phritis (Bright's disease) [1]. The entity was rediscovered in the
modern era by Dunnill eta! in a study of end-stage kidneys from
dialysis patients [2]. For a short time, ACKD was thought to be
a consequence of hemodialysis; however, more recent work has
shown convincingly, as Simon had intimated more than 100
years ago, that the cysts develop in kidneys damaged by
primary and secondary renal diseases [3—5]. Dialytic therapy
simply extends the time during which the cysts can develop.
The case selected for this Nephrology Forum illustrates
several central features of ACKD: (I) it is a bilateral condition;
(2) it can antedate the clinical recognition of end-stage renal
failure; (3) in the early stages, ACKD is asymptomatic and is
usually discovered inadvertently in the course of abdominal
imaging procedures; (4) renal epithelial hyperplasia plays an
integral role in cystogenesis [2, 5—71; (5) in certain hosts,
multifocal hyperplasia can progress to adenoma and therefrom
to adenocarcinoma [8, 9]; (6) malignant transformation is more
common in males than in females, and in blacks than in whites
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Fig. 1. A Unenhanced CT scan showing 3.5 cm diameter mass in the lower pole of the left kidney. Hypodense area (cyst) is visible in right kidney.
B High magn/Ication view of tumor mass in left kidney. (Courtesy of Errol Levine, MD, PhD.)
[10, 11]; (7) surgical treatment can accelerate the timetable for
instituting dialytic therapy in patients with renal carcinoma.
Clinical features. Acquired cystic kidney disease has been
described in nearly every type of renal disease that causes
progressive renal insufficiency, with the exception of the hered-
itary cystic disorders. More than 50% of patients dialyzed for 3
years or longer exhibit radiologic evidence of multiple renal
cysts. No single primary renal disease appears to promote
unusual vulnerability to ACKD, although the natural history
and epidemiology of the disorder have not been thoroughly
examined. The severity and duration of azotemia appear to be
critical factors in determining the extent of cyst development.
Cysts do not develop in other organs, in contrast to autosomal
dominant polycystic kidney disease (ADPKD). Occasionally
the disease is announced by severe retroperitoneal or intrarenal
hemorrhage with or without hematuria, cyst infection, erythro-
cytosis (perhaps secondary to increased renal erythropoietin
production), or distant metastasis from a malignant renal neo-
plasm [3, 5].
Acquired cystic kidney disease is reversible in some but not
all subjects since restoration of renal function to relatively
normal levels by transplantation causes regression of the cysts
and marked atrophy of the native kidneys in a high percentage
of patients [12, 13]. Some native kidneys continue to develop
cysts after renal transplantation, and it is conceivable that in
these cases, renal function remains significantly compromised,
thereby maintaining the cystogenic state [14].
Renal cancer, recognized in the seminal report by Dunnill et
al [2], is the most serious complication of ACKD [3, 5—7,
13—15]. In patients with ACKD, the risk of developing adeno-
carcinoma or other renal malignancies is sevenfold greater in
males than in females, as opposed to a twofold greater risk for
males in the U.S. population at large [5, 11]. Metastasis of renal
cancers in ACKD has been reported in approximately 20% of
cases [5, 8]. The rare appearance of malignant tumors in the
native kidneys of individuals who have received functioning
renal allografts suggests that the final step in progression from
cyst to adenoma to adenocarcinoma may not be reversible by
correction of the uremic environment.
A recent study suggests that the propensity for developing
malignant tumors is directly related to kidney weight (size);
kidney size in ACKD in turn depends on the total volume of
renal cysts and the proliferation of epithelial cells in the cyst
walls [9]. The relation between kidney size and the propensity
for developing malignant tumors is in accord with the hypoth-
esis that malignant neoplasia in ACKD is a multistep process
that begins in terminally differentiated renal tubules and ends in
adenocarcinoma (Fig. 4) [7, 9, 16]. I will return to this hypoth-
esis later.
Structural basis. Microdissection studies have confirmed in
ACKD, as in the hereditary cystic disorders, that the cysts
develop in renal tubules [17]. Analysis of ACKD cyst fluid and
histochemical studies of ACKD cyst epithelium suggest that
most of the cysts derive from proximal tubules [5, 17]. The
epithelium lining the cysts is typically hyperplastic (Fig. 3), and
multifocal adenomas ranging in size from a few hundred mi-
crons to several millimeters in diameter are not uncommon.
Individual cysts appear to have a common mode of develop-
ment in all renal cystic disorders. One or more epithelial cells in
a renal tubule segment apparently initiate proliferation that is
constituitively programmed or sustained by mitogenic factors,
thus leading to a marked increase in the surface area of the
tubule wall. Fluid that fills the resultant cavity derives from
glomerular filtrate and transepithelial solute and fluid secretion.
The interstitial matrix is infiltrated with inflammatory cells,
which may modify renal tubule basement membranes and
deposit type-l collagen within the interstitium. The initial stages
of cyst formation seem to be analogous to the formation of
multifocal benign tumors, except that in the case of cysts, the
"tumors" are filled with fluid rather than with cells and necrotic
debris [7].
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Fig. 2. A MR scan showing lucent cysts in both kidneys. B High magn/Ication view of tumor mass in left kidney. C High magnification view of
tumor mass in left kidney after enhancement with gadolinium. (Courtesy of Errol Levine, MD, PhD.)
In-vivo models of renal cyst formation. The understanding of nordihydroguaiaretic acid [NDGA]) causes cysts to develop in
renal cyst pathogenesis has been aided by the availability of otherwise normal kidneys. Each chemical cystogen appears to
several in-vivo animal models. The ingestion by rats of several damage renal epithelium; the initial injury then is followed by
chemicals (diphenylamine [DPA], diphenyithiazole [DPT], or focal tubule dilation and expansion. In this context, a cyst is
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Fig. 4. Hypothetical steps in the progression to adenocarcinoma. (See
text for details.)
Fig. 3. Sections of the left kidney, which was surgically removed. A
Section of end-stage parenchyma with early cyst formation, tubule cell
hyperplasia, and nuclear atypia, the possible forerunner of adenocarci-
noma. B More advanced cyst formation. C Papillary adenocarcinoma
invading renal capsule. (Courtesy of Walter Richardson, MD.)
differentiated from simple tubule dilation by the finding in the
epithelial wall of an increased number of circumferential cells
(Fig. 3). In addition to this criterion, Welling and Welling
propose that cysts must exceed a radial diameter of 200m to
differentiate them from dilated tubules [18].
The cystic disease caused by feeding diphenylthiazole can be
reversed by discontinuing exposure to the drug [19]. The
intensity of cyst formation caused by NDGA can be greatly
accelerated by exposing animals to enteric microbes or endo-
toxins [20, 21]. Such findings indicate that the progression of the
chemically induced cystic disorders requires ongoing exposure
to the original cystogen and, moreover, that -the process of
cystogenesis can be modified by secondary factors.
Extensive surgical excision of renal tissue (for example,
five-sixths nephrectomy) sufficient to produce azotemia causes
cysts to develop in the remaining parenchyma; the extent of
cyst formation can be increased by feeding the animals a diet
high in protein [22].
One-time administration of a long-acting corticosteroid to
neonatal rabbits causes cysts to develop in the cortical collect-
ing ducts within a few weeks [23]. Recent studies in different
strains of neonatal inbred mice suggest that the ability of
corticosteroids to induce cysts might depend on the animal's
genetic background [24]. The foregoing studies of in-situ cyst
formation prove that cysts can be provoked in neonatal and
a%'P\ •
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terminally differentiated renal tubules. In each case, the cysts
are characterized by increased numbers of cells within the wall
(hyperplasia).
In-vitro models of renal cyst formation. Newly described
in-vitro systems have helped elucidate some of the factors that
might regulate the formation and expansion of renal cysts.
Kidneys retrieved from fetal mice survive in organ culture and
have been used to study the biogenesis of in-situ cysts [25].
Hydrocortisone promotes cyst formation in vitro; the effect of
the steroid appears to be linked to an increase in the activity of
Na-K ATPase [261. Cysts develop in proximal tubules in a few
days, and the cysts regress when the hormone is removed from
the medium. No glomerular filtration occurs in fetal kidney
explants, so any fluid filling the cysts must be secreted across
the tubule wall.
An effect of aldosterone, mediated through potassium deple-
tion, has been implicated in the formation of cysts commonly
seen in the kidneys of individuals with Conn's syndrome [27].
Mendley and Toback have suggested that abnormal plasma
levels of sodium and potassium also might have a role in
promoting abnormal renal cell growth [161.
Individual cells of several continuous lines will proliferate
and form cysts when they are embedded in a gelled collagen
matrix in vitro [28—31]. McAteer et al showed that single
Madin-Darby canine kidney (MDCK) epithelial cells would
form cystic structures and enlarge progressively in a matrix of
type-i collagen [28]. The cysts had an orthodox polarity (cell
apex facing the cavity) in a matrix of type-i collagen; however,
the polarity of the same cells was reversed (cell apex facing
external medium) if the cysts were grown in an agarose matrix.
This novel study recasts the experimental investigation of cyst
biogenesis within the framework of developmental biology.
The MDCK cysts are relatively simple structures (Fig. 5).
The wall is a continuous monolayer of epithelial cells joined by
apical tight junctions surrounding a fluid-filled cavity under low
hydrostatic pressure [32]. In their logarithmic phase of growth,
individual cysts secrete fluid into the lumen at a mean rate of 1.8
jsL/cm2 day. The cavity fluid has Na and K concentrations
roughly equal to that of the medium, whereas the chloride
concentration can be greater than that of the medium [33]. Thus
MDCK cysts secrete Nat, K, and C1 into a cavity that is
formed by the progressive proliferation of the epithelial cells in
the cyst wall.
The MDCK cysts are as impermeable to water as mammalian
thick ascending limbs of Henle's loop, and water permeability is
not increased by vasopressin [34]. Thus the epithelium formed
by MDCK cysts is functionally equivalent to medullary thick
ascending limbs, except that the fluid is transported in a
secretory rather than in an absorptive direction. The mecha-
nism of fluid secretion in MDCK cysts appears to involve
primary secretion of electrolytes and passive osmotic move-
ment of water.
In media, MDCK cells require certain growth factors to
promote cyst formation [33]. The induction of cyst formation in
collagen gel requires activation of basolateral membrane ade-
nylate cyclase or the addition of cyclic AMP to the medium. We
have shown that MDCK cells have receptors for prostaglandin
E1 and arginine vasopressin (V, type) that are capable of
stimulating cyclic AMP production and thereby promoting cyst
induction and enlargement [33, 35]. Cyst formation and expan-
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Fig. 5. Progressive enlarge,nenl of a solitary living MDCK cyst sus-
pended in a transparent matrix of gelled collagen. MDCK cysts are
characterized by a single continuous epithelial layer enclosing a cavity
containing fluid with an electrolyte composition resembling the external
medium. In the early stages, the rate of increase in cyst wall surface
area (and total number of epithelial cells) is logarithmic. (From Ref. 32.)
sion also are promoted by cholera toxin, forskolin, methyl-
isobutylxanthine, and 8-Br-cyclic AMP. The rate of cyst expan-
sion can be diminished by ouabain, vanadate, bumetanide, and
amiloride analogues [32]. These findings raise the possibility
that, as in other secretory epithelia [36], chloride transport has
a rate-limiting role in the electrolyte secretion of MDCK cysts.
We can view MDCK cyst formation and expansion as de-
pending on at least two major processes: cell proliferation and
fluid secretion. Studies of MDCK cell monolayers grown on
plastic dishes indicate that agonists of cyclic AMP formation
can stimulate cell proliferation [33, 37, 38]. Recent unpublished
work suggests a narrow range of intracellular cyclic nucleotide
concentrations that promotes cellular proliferation (Neufeld T,
Grantham JJ, unpublished observations); high levels of cyclic
AMP might inhibit MDCK cell proliferation, as occurs with
other cells in vitro [38]. The fluid secretion component of cyst
biogenesis has been evaluated separately from cell proliferation
in polarized monolayers of MDCK cells [29]. Adenylate cyclase
agonists and intermediate components of this signal transduc-
tion pathway reversibly stimulated net fluid secretion. The
composition of the secreted fluid was similar to that of fluid in
intact cysts in collagen matrix.
One set of observations suggests, however, that cellular
proliferation and fluid secretion of MDCK cysts might not be
tightly linked under all circumstances. Ouabain, which inhibits
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the sodium pump and fluid transport in these cells, blocks the
secretion of fluid across polarized MDCK monolayers and stops
the enlargement of MDCK cysts in collagen gel. The cells in the
cysts, however, continue to proliferate in the presence of
relatively low (10—8 M) concentrations of ouabain, a drug that at
higher concentrations—l05 M—completely inhibits cellular
proliferation [321. In some cases, the cavities of the cysts
treated with low concentrations of ouabain become packed with
cells. This unusual effect of ouabain illustrates that fluid trans-
port and cell proliferation can be dissociated. The inhibition of
fluid secretion by low concentrations of ouabain allows the
proliferating epithelial cells to accumulate as a cellular mass,
rather than as a cyst. This finding supports the supposition that
renal cysts are in fact benign tumors filled with fluid.
The MDCK experiments afford a view of the behavior of cells
that are genetically programmed to proliferate endlessly upon
hormonal stimulation. In this sense, the MDCK model might
reflect behaviors similar to the hereditary cystic disorders. The
paradigm for evaluating cyst-forming behavior of renal cells in
vitro, based on experience with MDCK cells, also has been
used to study epithelial cells from normal human renal cortex
(NHK). Cyst formation by NHK cells is probably even more
relevant to the issue of cyst biogenesis in ACKD. Normal
human cortex cells obtained from primary cultures of human
renal cortex have been cultured in gelled type-i collagen matrix
[39]. The formation of cysts depended on the presence of
epidermal growth factor (EGF) and insulin in the medium.
Thyroxine and selenium, common additives to tissue culture
medium, were not essential for cyst induction, but the yield of
cysts and the rate of expansion were increased when these two
agents were present in medium along with EGF and insulin [39].
Neufeld, Douglas, and Grantham found that TGF was as
effective as EGF in promoting cyst induction and expansion
(Neufeld T, Douglas D, Grantham JJ, unpublished observa-
tions).
Agents that stimulate adenylate cyclase, when used in con-
junction with EGF and insulin, accentuated the induction and
progressive enlargement of NHK cysts [39]. Receptor-mediated
agonists included prostaglandin E1, arginine vasopressin, vaso-
active intestinal peptide, and parathyroid hormone. Cholera
toxin, forskolin, methylisobutylxanthine, and 8-Br-cAMP stim-
ulated the induction and progressive enlargement of cysts [39]
(Neufeld T, Douglas D, and Grantham JJ, unpublished obser-
vations).
Net fluid secretion across polarized monolayers of NHK cells
also was stimulated by several components of the adenylate
cyclase signal transduction pathway [29]. We have not directly
examined the effect of cAMP agonists on the proliferative
component of NHK cyst biogenesis; however, based on the
cellular appearance, it is clear that the enlargement of intact
cysts produced by these agents involves a marked increase in
the number of cells in the cyst wall, as has been more rigorously
documented for MDCK cysts [32]. Although individual NHK
cysts can grow to relatively large size in vitro (greater than 1
mm in diameter), we have not been able to propagate the cyst
cells indefinitely, unlike the immortal cells of the MDCK line, It
appears, therefore, that NHK cells obtained in primary cultures
of renal cortex are not transformed by maintenance in gelled
collagen.
The pathogenesis ofACKD in patients with progressive renal
insufficiency: A hypothesis (Fig. 4). In individuals with progres-
sively destructive renal disorders, ACKD develops pan passu
with the decline in renal function. Hypertrophy, not hyperpla-
sia, is the dominant response of surviving nephrons to the loss
of functioning tissue [40]. The explicit afferent signals that
initiate compensatory renal hypertrophy are not known. Cur-
rent opinion favors the view that specialized hormones or
renotropins are not importantly involved [40].
Acquired cystic kidney disease appears to be the response of
residual nephrons to profound parenchymal loss occurring over
relatively long periods during which epithelial hypertrophy
gives way to hyperplasia. These two cellular responses increase
the size of renal tubular structures that, were it not for the
accumulation of fluid, would result in a small, fibrotic kidney
studded with adenomas. Anatomic distortion created by the
intense interstitial fibrosis interferes with the normal flow of
urine through the surviving renal tubule segments and sets the
stage for accumulation of fluid within the hyperplastic renal
tubules. The contribution of glomerular filtration to the fluid
buildup probably is minimal given the severe degree of glomer-
ular sclerosis in end-stage kidneys. It seems reasonable to
suppose that the major source of fluid is transepithelial secre-
tion, and that the leading secretagogue candidate is parathyroid
hormone, which is persistently elevated in individuals who are
chronically azotemic. Other potential prosecretory hormones
include vasopressin, secretin [41], and vasoactive intestinal
peptide [40]. The relatively high levels of cyclic AMP in the sera
of dialysis patients also are consistent with the view that the
cyclic AMP system might be overactive in the uremic state [42].
The in-vitro studies I previously noted suggest that activation
of adenylate cyclase could accelerate cyst expansion, but that
the induction of proliferation requires a different mitogen such
as EGF or TGFa. No evidence indicates that either of these
growth factors is present or overabundant in end-stage kidneys.
On the other hand, Klotz et al found evidence of a unique
mitogenic factor in the sera of patients with end-stage renal
disease [43]. The factor appeared to be a peptide of between 15
and 30 kD, and different from other growth factors including
EGF, basic fibroblast growth factor, and platelet-derived
growth factor. A substance with these features could be the
hyperplasia-inducing agent that is potentiated by the adenylate
cyclase agonists in the creation of cysts.
Parathyroid hormone is believed by some researchers to
promote neoplasia in patients with primary or secondary hyper-
parathyroidism [44]. Conceivably, high-intensity day-to-day
activation of adenylate cyclase by PTH could, in a genetically
susceptible azotemic host, promote sustained activation or
mutation of one or more proto-oncogenes that transform cells
and produce malignant tumors. In addition to the foregoing
candidate agonists, the higher incidence of renal adenocarci-
noma in males than in females and the multifocal origin of such
cancers support the view that several factors might occur in
parallel or sequentially to push the proliferative process toward
malignant transformation.
Similar multistep scenarios have been suggested as underly-
ing the development of colonic adenomas and adenocarcinomas
[45]. The plausibility of this hypothetical schema for the devel-
opment of renal cysts and the eventual transformation to a
malignant state is underscored by recent studies that demon-
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strate how normal human renal cortex cells, immortalized by
treatment with nickel [II], can be further transformed to a
malignant state upon nuclear insertion of a mutated rasonco-
gene [46, 47].
Reworking Fine's hypothesis [40] (Fig. 4), I suggest that: (1)
With the progressive destruction of functioning renal tissue, the
surviving nephrons are first affected by the forces of hypertro-
phy. (2) With a severe reduction in renal function, several
mitogenic forces emerge, including alterations in plasma elec-
trolyte levels [16], diminished excretion of protons [27], accu-
mulation of adenyl cyclase hormone agonists [7, 44], and the
elaboration of autocrine or paracrine growth factors [43, 48]. (3)
The combined forces of hypertrophy and hyperplasia promote
the induction and progressive expansion of renal tubules to
form cysts. (4) In genetically susceptible individuals, these
combined forces possibly are sufficient to activate latent onco-
genes [491. (5) Alternatively, other provoking factors might
emerge, such as environmental chemicals, transforming vi-
ruses, or male sex hormones, that complete the multistep
process of oncogenesis.
Epilogue. Those of us who have labored in the ACKD field
should not rise to premature self-congratulation for our expo-
sitions until we have read several humbling passages from an
article written by John Simon, F.R.S., in 1847 [1]. In his paper
entitled "Sub-acute inflammation of the kidney," he made
observations on some wholly unappreciated features of chronic
"Bright's Disease":
I shall endeavour rather to fix attention on
changes hitherto little observed; changes which com-
mence in inflammation of the kidney, and tend com-
pletely to disorganise it, but which run a slow and
insidious progress during life, and often leave in the
dead body no such obvious traces as would strike the
superficial observer.
The latent processes to which I refer are among the
most interesting and curious in the whole compass of
pathology; consisting (1) in the more or less complete
obliteration of the kidney; and (2) in the attempt to
compensate for this, by the organization of a new
secretory apparatus.
An examination of this latter process,—by which (as
I shall presently show) vesicles are substituted for the
normal tubularity of the gland,—will lead me to ex-
plain the origin of those large renal cysts, so well
known in the dead-house—
They exhibit great variety in size; they are seen
every day as small as mustard seeds; they have been
seen as large as cocoa nuts. Thus, they obviously
range from a very conspicuous largeness to a size at
which the naked eye loses them. On microscopical
examination of cysted kidneys, the same uninter-
rupted gradation of size is seen to repeat itself.
Not only did Simon clearly describe ACKD, but he was
probably the first to postulate cell proliferation and net fluid
secretion as fundamental pathophysiologic processes in cysto-
genesis:
The materies morbi seeks to effect its discharge by
means of an increased activity in the secreting func-
tions of the kidney; it stimulates it; and the result of
the stimulation is not so much an increase of the
watery secretion as it is an augmented cell-growth in
the tubules of the gland.
During the growth of the cysts, they frequently
exhibit an endogenous formation of cells which line
them as an epithelium: and in this condition (which
commonly does not continue if they become very
large) they present a curious similarity to the vesicles
of the thyroid gland, and are, no doubt, like these,
organs of secretion.
Need one question why we call our work re-search?
Questions and answers
DR. JEROME P. KASSIRER (Editor-in-Chief, New England
Journal of Medicine, Boston, Massachusetts): How clear is the
evidence that cysts originate in renal tubule cells rather than in
other renal cells? Has anyone studied serial microscopic sec-
tions to document a connection between the tubule and the
cysts?
DR. GRANTHAM: Microdissection studies in the early stages
of cyst formation indicate that cysts derive from renal tubules in
the hereditary and non-hereditary forms of renal cystic disease
[50, 51]. Lambert found connections between cysts and tubules
in dissection and serial section studies of autosomal dominant
PKD [52] and, in a scanning electron microscope study of the
interior surfaces of cysts, my colleagues and I observed that
tubules opened into about one-fourth of the cysts [53]. I think
there is little question that cysts, both in acquired and heredi-
tary disorders, arise in tubular epithelia extending from Bow-
man's capsule to the tip of the collecting duct.
DR. PAUL KURTIN (Director, Dialysis Unit, New England
Medical Center): What is the effect of uremic serum on in-vitro
cyst growth? Cysts continue to grow in dialyzed patients.
Therefore, what substance not removed by dialysis could affect
cyst growth?
DR. GRANTHAM: To my knowledge, no one has rigorously
tested the effect of uremic serum on cyst growth in vitro. We
have performed a few preliminary studies using the MDCK
in-vitro model of cysts, and we found that normal and uremic
sera from dialysis patients had no detectable differences in
promoting an increase in the rate of cyst growth. These studies
certainly bear repeating.
Indeed, acquired cysts do continue to grow in dialyzed
patients; therefore the dialysis procedure does not remove a
humoral factor, if in fact an as-yet-undetected humoral factor
exists and has a role in the propagation of acquired cystic
disease.
DR. KURTIN: Does ouabain inhibit cyst growth?
DR. GRANTHAM: Ouabain does inhibit growth in vitro, as I
noted in my presentation. But at low concentrations the glyco-
side turns off the secretion of solute and water into the cysts
without stopping cyst wall cell proliferation. Therefore, at low
ouabain concentrations one produces tumors in vitro; at high
concentrations, cyst growth can be halted. To my knowledge,
the effects of ouabain or other digitalis preparations have not
been examined in animal models of cystic disease or in human
subjects.
DR. KURTIN: Non-uremic patients with diseases such as
tuberous sclerosis develop renal cysts. Are those cysts different
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than acquired cysts in uremia? Could we learn more about
cystogenesis by studying these patients?
DR. GRANTHAM: Your question gives me license to unhar-
ness some speculation. The cysts of tuberous sclerosis are lined
by unusual proliferating epithelium with a distinct eosinophilic
cytoplasm that sets them apart from other types of cysts. The
cysts are found in kidneys that also harbor hamartomas and
angiomyolipomas, which are solid masses of tissue. Tuberous
sclerosis very well might represent the natural expression of a
proliferative renal epithelial disorder in which the proliferation
of cells is dissociated from the accumulation of fluid. In other
words, those proliferating cells capable of secreting fluid may
form cysts; those that lack the secretory apparatus may form
tumors. I think there is much to be learned about cystogenesis
from the study of individuals with tuberous sclerosis.
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center): Several of the modulators of
cystogenesis you suggested have systemic effects. Is there any
evidence that patients with acquired cystic kidney disease
develop extrarenal lesions?
DR. GRANTHAM: Researchers have looked for clinical evi-
dence of extrarenal pathology in patients with acquired cystic
disease. Nothing has been found to my knowledge.
DR. MADIAS: You mentioned nephron hypertrophy as the
initiator in the process of cystogenesis. If it is, settings such as
unilateral renal agenesis with superimposed renal disease and
oligomeganephronia might display some special predilection to
acquired cystic disease. Are there any observations of in-
creased frequency of cystic disease in such conditions?
Da. GRANTHAM: Not to my knowledge.
DR. KASSIRER: How much should we worry about malignant
transformation of acquired cystic disease? Clearly, malignant
transformation occurs, and some patients die of malignancy.
But how often we screen these patients with imaging studies is
a function of the seriousness of the condition in this population
of patients. Just how often do patients on chronic dialysis die of
metastatic renal cancer?
DR. GRANTHAM: That's an excellent question, and at this
juncture, there is no clear answer. We have seen 7 patients with
renal cancers at the University of Kansas and the Kansas City
Veterans Medical Center; 2 of the cancers had metastasized.
We are actively seeking patients with these types of tumors in
our nephrology program. We screen most new dialysis patients
by ultrasound as part of the introduction to the program.
Screening is repeated on an ad-hoc basis, but we aim to
examine each patient at approximately 3-year intervals and to
examine any time a patient develops suspicious symptoms. We
just reported a small prospective study in which we examined a
cohort of dialysis patients by contrast-enhanced CT [541. Renal
cysts either worsened or developed in 87% of 30 subjects; 2
(7%) developed renal malignancies.
One of the cancers was found in an elderly man who had a
renal mass on CT, but who was too cachectic for exploratory
surgery. Had we not known about the renal mass, we probably
would have ascribed his subsequent death to a cardiovascular
cause. A limited autopsy was permitted, and indeed he had a
renal carcinoma. The extent of metastasis is unknown.
There might be many cases like this. Who is to say whether
cachexia and death are due to malignancy or to cardiovascular
causes if we have not looked carefully for cancer in these
patients? The autopsy rate is probably not very high for dialysis
patients, and we might be overlooking more of these patients
than we might imagine.
Can we justify repeated CT screening of every dialysis
patient? I doubt that a cost-benefit analysis would justify such
an approach given the amount and the quality of data we have
in hand. MacDougall and colleagues report a direct relationship
between renal size and the occurrence of cancer in the kidneys
of dialysis patients [91. We recently used this finding to justify
nephrectomy in a dialysis patient with marked renal enlarge-
ment due to cysts. We found renal adenocarcinoma (3.0 cm) in
one of the kidneys.
I think we can justify ultrasound screening of dialysis patients
on a regular basis (every 1—3 years), reserving CT scanning for
those with enlarged kidneys or obvious renal masses. In the
final analysis, prospective and retrospective studies should be
undertaken to determine the natural history of this disease and
to establish guidelines for screening.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): Both in acquired cystic and in autoso-
ma! dominant polycystic kidney disease, the cysts are often
filled with congealed material that might make it difficult to
distinguish malignant transformation within the cyst from a
benign cyst. Are there good studies of imaging procedures that
distinguish malignant from benign cysts in either condition?
DR. GRANTHAM: I agree. Differentiating between a neoplasm
and cysts in autosomal dominant PKD can be a difficult task.
We use CT to look for mass lesions that enhance with intrave-
nous contrast material. An iodinated contrast agent is used with
CT and, as in the current case, gadolinium is used with MRI.
One also looks for thickening of cyst walls. Arteriography is
useful to demonstrate neovascularization.
DR. BRIAN J.G. PEREIRA (Division of Nephrology, New
En gland Medical Center): Given the facts that transplant recip-
ients have a much higher risk of malignancy and that most
patients have been on dialysis for a long time, one would expect
renal adenocarcinoma to be high on the list of post-transplan-
tation malignancies. This, however, is not the case. Do you
think that the uremic state is essential for the development of
overt adenocarcinoma, or do these potentially malignant lesions
undergo ischemic necrosis after transplantation?
DR. GRANTHAM: I'll have to take issue with one of your
postulates. I'm aware of several anecdotal reports of patients
with successful renal transplants who later developed cancer in
their native kidneys. Some transplant surgeons feel strongly
that in certain cases the native kidneys should be removed prior
to transplantation. Why would cancer develop if the uremic
state has been corrected by renal transplantation? I think there
is a point in the multistep process when the cyst or adenoma has
not been malignantly transformed and is still a reversible
structure. Once this point is crossed, the cells escape from all
control, the irreversible and final step noted in Figure 4. That
step could occur before the patient receives a renal transplant
but become clinically apparent later. In those lucky patients
who receive their transplants before malignant transformation
occurs, cancer might be less likely to develop in the native
kidneys.
DR. ALAN MURRAY (Fellow, Division of Nephrology, New
England Medical Center): Do the epithelial cells of acquired
cystic disease demonstrate neoplastic growth in cell culture?
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